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ABSTRACT
Objectives: To examine the relationship between psychiatric
symptoms, cognitive performance, functional capacity and
quality of life in Alzheimer’s disease (AD), and change in
the Health Utilities Index (HUI)—Mark III, a widely used
generic, multiattribute preference-based health-status classi-
ﬁcation system.
Methods: Follow-up data were obtained from caregiver
proxy raters at 3, to 6, and 9-months postrandom assignment
concerning 421 patients with AD, living with at least
one caregiver in a noninstitutional setting, who partici-
pated in the Clinical Antipsychotic Trial of Intervention
Effectiveness—AD of antipsychotic medication. Spearman
rank correlations, multivariate linear regression, and mixed
modeling were used to examine the correlates of change in
the HUI.
Results: HUI scores decreased by an average of -0.061 over
9 months. Analysis revealed weak bivariate, and largely, non-
signiﬁcant multivariate relationships between change in
HUI scores and sociodemographic characteristics, psychiatric
symptoms, and cognitive performance. There were highly
signiﬁcant associations between decreases in health utilities
and change in the AD Cooperative Study for Activities of
Daily Living scale (ADCS-ADL) and AD-Related Quality of
Life (ADRQoL) (both P < 0.001), even after controlling for
other factors. Adjusted R2 values ranged from 0.14 to 0.20.
Conclusion: In AD patients requiring antipsychotic treat-
ment, only weak relationships were found between changes
in the HUI and sociodemographic and clinical indicators.
While functional capability and quality of life showed more
signiﬁcant associations, less than 20% of the variance in
health utility could be explained. Signiﬁcant cognitive impair-
ment and the need to rely on proxy raters may limit the
usefulness of utility measurement in AD patients with serious
behavioral symptoms.
Keywords: Alzheimer’s disease, health utilities index, quality-
adjusted life-years.
Introduction
Alzheimer’s disease (AD) is a costly and debilitating
chronic neurodegenerative disorder that affects 5 to 8
million Americans at an estimated cost of $148 billion
annually [1,2]. Currently, AD is the seventh leading
cause of death among all Americans and ﬁfth leading
cause among those 65 years or older [2]. It is charac-
terized by progressive memory loss and decline in
other cognitive functioning and is associated with a
broad range of mood and behavioral symptoms [3,4].
Caregivers also experience signiﬁcant psychological
and physical comorbidity [5], in addition to reductions
in quality of life [6]. Due, in part, to the aging of the
population, the prevalence and costs associated with
AD will continue to rise well into the foreseeable
future [7].
Although no treatment cures, reverses or arrests
AD, pharmacological treatments continue to be devel-
oped to slow the progression of the disease [8–14]
and to ameliorate behavioral symptoms [3,15]. With
increasing development of AD treatments, there will be
a need to compare the relative cost-effectiveness of
different AD interventions, preferably using a stan-
dardized measure of health utility [16–18]. Though
not as inﬂuential on US decision-makers as in other
developed countries, more than 10 years ago, the US
Public Health Service Task Force on Cost-Effectiveness
in Health and Medicine [19] speciﬁcally recommended
that health states in cost-effectiveness analysis be
expressed as quality-adjusted life-years (QALYs), years
of life rated on a cardinal scale from 0 (worst possible
health) to 1 (perfect health), with health states worse
than death represented as negative values. QALYs are
typically measured by multiplying the time spent in
a health state by quality weights determined using
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generic health utility measures such as the Quality of
Well-Being (QWB) scale [20], the EuroQoL instrument
[21], and three generations of the Health Utilities
Index (HUI-I, -II, and -III) [22]. Each of these instru-
ments assigns a quality of life state based on responses
to a health-status questionnaire weighted using previ-
ously derived weights from other populations. Though
potentially useful in assessing the cost-effectiveness
of AD-related therapies, developers of generic-
preference-based measures have only validated their
instruments for use in general populations and not for
people with speciﬁc diseases, let alone signiﬁcant cog-
nitive impairment. This is important because if health
utilities lack sensitivity to health-status changes in AD,
analysts conducting cost-effectiveness evaluations of
AD interventions will need to look beyond QALYs to
identify other, more appropriate measures of the net
health beneﬁts achieved.
Due to concern that instruments such as the HUI,
EuroQoL, and QWB may lack sensitivity to disease-
speciﬁc effects [6,23–26], the relationship between
preference-based indices and more commonly used
clinical indicators has been examined among patients
with a variety of conditions [27–33]. Although some
studies have examined the relationship between
cognitive performance, psychiatric symptoms, and
functional capacity and health utility scores in AD
patients [24,34–36], no study has examined the rela-
tionship between all three of the former measures
and health utility scores using a common data set, or
examined the relationship between health utility
scores and AD-speciﬁc measures of quality of life
with adjustment for sociodemographic and other
factors. Furthermore, only one longitudinal study has
been reported so far [37]. This study demonstrated
that the EuroQoL EQ-5D instrument could be used
to rate health utilities in AD over time, with positive
associations being identiﬁed between lower health
utilities and worse cognitive performance and greater
psychiatric symptoms after controlling for other
factors.
In the context of “general scarcity of data on utilities
in AD, and some limitations of existing information
[38],” the present study uses data from a 9-month
randomized trial to examine the relationship between
cognitive performance, psychiatric symptoms, func-
tional status, and quality of life in AD and change in the
Health Utilities Index, Mark III (HUI-III) a well-known
generic, preference-based health-status classiﬁcation
system. In doing so, we use longitudinal data to better
assess the construct validity of the HUI-III in popula-
tions with AD, and to determine whether disease-
speciﬁc measures can be used to predict QALYs when
direct measurement is unavailable. In doing so, we use
the HUI-III and other measures from the Clinical
Antipsychotic Trial of Intervention Effectiveness—AD
(CATIE-AD) [39,40]. The HUI-III is the most widely
used generic health utility measure in previous AD
studies [24,35,36,41].
Methods
Sample and Source of Data
To evaluate the effectiveness of second-generation
antipsychotics (SGAs) in the treatment of psychosis or
aggression in patients with AD, the National Institute
of Mental Health (NIMH) initiated the CATIE-AD
trial. CATIE-AD used an experimental study design to
compare the effectiveness of SGAs (olanzapine, risperi-
done, and quetiapine) that were available in the United
States in January 2001 and commonly used in demen-
tia patients and placebo. The background, rationale,
and methods of CATIE-AD have been presented in
detail elsewhere [39]. The trial was conducted between
April 2001 and November 2004 at 45 clinical sites in
the United States. Effectiveness and cost-effectiveness
ﬁndings have been reported previously [15,40].
Eligible participants fulﬁlled criteria dementia of the
Alzheimer’s type (DSM-IV) or probable AD [42] on the
basis of history, physical examination, results of struc-
tural brain imaging, and Mini-Mental State Examina-
tion (MMSE) scores ranging from 5 to 26 [43]. They
also had to be ambulatory outpatients living at home or
in assisted living, in addition to having clinically severe
delusions, hallucinations, aggression, or agitation,
occurring after the onset of symptoms of dementia. A
score of “moderate” or greater was required during the
week before randomization on the brief psychiatric
rating scale (BPRS) [44] or a severity score of “moder-
ate” or more was required on the delusion, hallucina-
tion, agitation, or “aberrant motor behavior” items of
the Neuropsychiatric Inventory (NPI) [45]. A caregiver
who livedwith or visited the participant at least 8 hours
per week and 3 days per week was required to contrib-
ute to the assessments.
Participants were excluded if they had schizophre-
nia, schizoaffective disorder, delirium, or probable
vascular dementia (by NINDS-AIRENS criteria) [46].
Other exclusion criteria were described previously
[15]. Participants were allowed to continue to receive
stable doses of various medications, including cho-
linesterase inhibitors, memantine, antihypertensives,
anti-inﬂammatory drugs, anticoagulants, laxatives,
and diuretics, among others. Concurrent uses of antip-
sychotics, antidepressants, anticonvulsants as mood
stabilizers or regularly prescribed benzodiazepines
were prohibited. The trial was designed to encourage
prescribing as close as possible to typical clinical prac-
tices, allowing for ﬂexibility of dosing. All patients and
caregivers received basic information and education
about AD, its clinical course, cognitive and behavioral
problems, symptomatic behaviors, management ap-
proaches, and medications. Caregivers were offered
two voluntary counseling sessions in the ﬁrst 18 weeks
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and the ability to talk with a counselor on an
as-needed basis.
Overall, CATIE-AD included 421 ambulatory out-
patients with dementia of the Alzheimer’s type. They
lived with at least one caregiver and had clinically
severe delusions, hallucinations, aggression, or agita-
tion. The study was reviewed and approved by the
NIMH data safety and monitoring board and the insti-
tutional review board for each site. Written informed
consent was obtained from participants or their legally
authorized representatives and from the study part-
ners. In addition to baseline data, follow-up data were
obtained from caregiver proxy raters at 3-, 6-, and
9-months postrandom assignment.
Measures
Health utilities were measured using the HUI-III. The
HUI-III consists of a health-status classiﬁcation
system, which describes 927,000 unique health states,
and a preference or utility function which may be
used to calculate the desirability of each state [47].
The classiﬁcation system assesses capacity in eight
dimensions—vision, hearing, speech, ambulation, dex-
terity, emotion, pain or discomfort, and cognition
(including memory and thinking ability), with ﬁve to
six levels of functioning associated with each attribute,
varying from highly impaired to normal. The develop-
ers of the HUI-III collected preference measures from
a population based in Hamilton, Ontario, Canada.
These preference measures are used to score each of
the 927,000 unique health states described by the HUI-
III on a scale from 0 (dead) to 1 (perfect health), with
negative values indicating states worse than death.
We examined the relationship between HUI-III
scores and sociodemographic characteristics such as
age, sex, race, marital status, and education. We also
examined the relationship between HUI-III scores and
cognitive performance, psychiatric symptoms, func-
tional status, and quality of life in AD. Global cogni-
tive functioning was measured on a scale from 0 to 30
using the MMSE [43], which consists of 11 questions
testing cognition in ﬁve areas: orientation, registration,
attention and calculation, recall, and language. The
MMSE has demonstrated validity and reliability and is
frequently used to track the progression of cognitive
impairment associated with AD [37,48]. Lower scores
indicate poorer performance.
Psychiatric symptoms were assessed using the NPI,
a valid and reliable measure frequently used to quan-
tify behavioral disturbances in patients with AD and
other dementia [45,49,50]. The NPI evaluates 12 neu-
ropsychiatric disturbances: delusions, hallucinations,
agitation, dysophoria, anxiety, apathy, irritability,
euphoria, disinhibitation, aberrant motor behavior,
nighttime behavior disturbances, and appetite and
eating abnormalities. NPI scores are calculated for
each domain by multiplying frequency by intensity.
Global NPI scores are produced by totaling individual
subscale scores, with higher scores indicating more
severe neuropsychiatric problems.
Physical functioning was measured using the Alz-
heimer’s Disease Cooperative Study Activities of Daily
Living scale (ADCS-ADL). The ADCS-ADL consists of
23 questions assessing performance in ﬁve basic ADLs
(eating, walking, toileting, bathing, and grooming)
and 18 instrumental ADLs (telephoning, shopping,
reading, writing, conversing, etc.) [51]. Performance
on each ADL is scored from 0 (nonperformance or the
need for extensive help) to the highest score—2, 3, 4,
5, or 7 (independent performance). Total scores range
from 0 to 78, with lower scores indicating greater
impairment in functioning.
Social and occupational functioning is measured
using the valid and reliable AD Dependence scale,
which was designed to evaluate care requirements
resulting from social and occupational deﬁcits [52,53].
In addition to assessing gross forms of dependency
such as the need for assistance in self-care activities,
the Dependence scale assesses relatively subtle forms of
dependency such as the need for reminders or advice in
managing daily activities and the need for help in
remembering appointments, events, or names. Patient
Dependence Scale total scores are determined by
summing answers to 11 “yes or no” questions and two
questions with three categories (“no,” “occasionally,”
and “frequently”). Total scores range from 0 to 15,
with higher scores indicating greater dependence.
Finally, quality of life was measured using the
AD-Related Quality of Life scale (ADRQoL) [54].
Quality of life is a broad multidimensional concept
that reﬂects a person’s sense of well-being, self-esteem,
and satisfaction with life vis-à-vis achieving goals,
receiving care, and exercising control over one’s cir-
cumstances [55]. Difﬁculties in measuring quality of
life directly in patients with AD or other dementia [56]
informed development of the ADRQoL, a valid and
reliable measure, which relies on informant observa-
tion. The ADRQoL assesses quality of life in ﬁve
domains: social interaction, awareness of self, feelings
and mood, enjoyment of activities, and response to
surroundings [57,58]. A total score is generated by
summing up scores across individual domains. Scores
are expressed as a percentage of the total possible
score, with higher scores indicating better quality of
life during the 2 weeks preceding the interview.
Analysis
The analysis proceeded in several steps. First, we
examined the characteristics of the study sample at
baseline. Second, we calculated the average change in
HUI-III, NPI, MMSE, AD Dependence, AD ADL, and
ADRQoL scores between baseline and 3-, 6-, and
9-months postrandom assignment. We also calculated
the average change in each of these measures after
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pooling observations from all three time periods.
Third, we used Spearman rank correlations to examine
the bivariate relationship between change in HUI-III
score and baseline sociodemographic characteristics
and change in the ﬁve clinical/disease-speciﬁc indica-
tors. Fourth, we employed ordinary least squares
regression to describe the relationship between change
in health utility score and sociodemographic charac-
teristics (age, sex, race, marital status, and education),
as well as the ﬁve clinical/disease-speciﬁc indicators
examined. Analyses were conducted separately at all
three time periods and with data from all periods
pooled. To account for clustering of observations
across individuals over time, the pooled analysis was
also conducted using mixed models with Proc Mixed
in SAS 10.0 (SAS Institute, Cary, NC). This involved
estimation of a random effects model with robust stan-
dard errors.
Results
Altogether 421 patients entered the study, with the
proportion of patients completing monthly assess-
ments declining from 86.5% at 3 months to 78.6% at
6 months to 74.6% at 9 months. Table 1 reports base-
line demographic and clinical/disease characteristics.
The average age was 77.9 years. Approximately
60.0% of patients were receiving treatment with a
cholinesterase inhibitor at baseline; 16.0% anti-
inﬂammatory drugs, and 30.0% vitamin E. Upon
randomization, two-thirds (66.3%) were assigned to
an SGA, one-third (33.7%) to placebo. The majority
of patients were female (55.8%), married (59.1%),
and Caucasian (79.0%). Relatively few (28.7%) were
college educated.
The distribution of patients across MMSE scores
changed during the course of the study. The average
MMSE score was 15.0 at baseline before declining by
an average of 0.95, 1.6, and 2.3 points over 3, 6, and
9 months, respectively (Table 2). Average NPI scores
were 36.8 at baseline before declining by 13.7 points
over 3 months, 15.1 points over 6 months, and 17.2
points over 9 months. Whereas AD Dependence Scale
total scores increased by an average of 1.2 points over
9 months from a baseline score of 7.9, ADCS-ADL
scores declined by an average of 9.6 points over
9 months from an average baseline score of 39.4.
ADRQoL scores increased from 67.3 to 71.6 points,
on average, during the 9-month study period.
Average global utility scores measured using the
HUI-III were 0.184 at baseline, with individual scores
ranging from -0.291 (worse than death) to 1.0 (perfect
heath). On average,HUI-III scores declined over time to
0.162 at 3 months, 0.148 at 6 months, and 0.123 at
9 months. Table 3 shows pairwise correlations with
HUI-III score. Results reveal moderate statistically sig-
niﬁcantly correlations between HUI-III scores at base-
line and all ﬁve clinical/disease-speciﬁc indicators, with
higher utilities being associated with stronger social
and occupational functioning (lower AD Dependence
score), better physical functioning (higher ADCS-ADL
score), fewer psychiatric symptoms (lower NPI score),
stronger cognitive functioning (higher MMSE score),
and better quality of life (higher ADRQoL score) (all
P < 0.001). They also reveal weak but statistically sig-
niﬁcant correlations between change in the HUI-III and
change in the MMSE and NPI over time. Thus, change
in HUI-III scores was inversely related to change in the
NPI (P < 0.01 to 0.001) and directly related to change
in the MMSE (P < 0.10 to 0.001). This is in contrast to
weak to moderately strong signiﬁcant correlations
between the HUI-III and the remaining three disease-
speciﬁc indices, with change in HUI-III scores being
Table 1 Characteristics of study sample at baseline (n = 412–
421)
Mean SD Minimum Maximum
Age 77.860 7.462 51.000 103.000
Female 0.558 0.497 0.000 1.000
Non-Hispanic Caucasian 0.790 0.408 0.000 1.000
Married 0.591 0.492 0.000 1.000
Some college or more 0.287 0.453 0.000 1.000
Cholinesterase inhibitor 0.601 0.143 0.000 1.000
Health Utilities Index 0.184 0.250 -0.291 1.000
Neuropsychiatric Inventory 36.879 18.290 3.000 104.000
Mini-Mental State Exam 15.002 5.801 4.000 29.000
AD Dependence total score 7.852 2.686 0.000 15.000
ADCS-ADL scale 39.443 17.112 2.000 76.000
AD-Related Quality of Life 67.308 14.655 18.710 100.000
n varies depending on the number of missing values.
ADCS-ADL,Alzheimer’s Disease Cooperative Study for Activities of Daily Living.









Change in Health Utilities Index -0.022 -0.036 -0.061 -0.039
Change in Neuropsychiatric Inventory -13.654 -15.119 -17.208 -15.234
Change in Mini-Mental State Exam -0.950 -1.602 -2.275 -1.569
Change in AD Dependence total score 0.577 0.940 1.238 0.901
Change in ADCS-ADL scale -3.798 -7.259 -9.581 -6.713
Change in AD-Related Quality of Life 4.292 5.180 4.344 4.599
n varies depending on the number of missing values.
ADCS-ADL,Alzheimer’s Disease Cooperative Study for Activities of Daily Living.
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inversely related to change in AD Dependence (all
P < 0.001) and directly related to change in both the
ADCS-ADL (all P < 0.001) and ADRQoL (all P <
0.001). There is also evidence to suggest a weak inverse
association between being married and change in HUI-
III score (P < 0.01 and P < 0.05 in the 9-month and
pooled analyses, respectively).
Table 4 presents estimated regression coefﬁcients
for age, sex, race, marital status, education, MMSE,
NPI, AD Dependence, ADCS-ADL, and ADRQoL.
Overall, 14% to 20% of the variance could be
explained across the four linear regression models esti-
mated. Furthermore, results reported in the random
effects model do not differ from those reported in the
pooled ordinary least squares model. In the multivari-
ate analyses, change in ADRQoL scores was found to
be positively related to change in HUI-III scores at all
three follow-up visits (P < 0.01, P < 0.001, P < 0.001),
as well as in the pooled and mixed model (i.e., random
effects) results for all visits (both P < 0.001). This is
also true for change in the ADCS-ADL scale, which
was found to be positively related to change in HUI-III
score at all three follow-ups (P < 0.001, P < 0.05,
P < 0.001), as well as in the pooled and random effects
analyses (both P < 0.001). Thus, in the pooled/random
effects analyses, a 1-point increase on both the ADCS-
ADL and the ADRQoL corresponded to an increase of
0.004 on the HUI-III (standardized regression coefﬁ-
cients = 0.211 and 0.221, respectively).
These ﬁndings stand in contrast to change in the
MMSE, which did not show statistically signiﬁcant
relationships in any analysis, as well as to change in
AD Dependence and NPI, which proved statistically
signiﬁcant in just two and three analyses, respectively.
A 1-unit increase in dependency was associated with a
-0.009 decrease in the HUI-III in the pooled and
random effects analyses (both P < 0.05), whereas a
1-unit increase in the NPI was associated with -0.001
decline in the HUI-III at both 6 months (P < 0.10) and
across all time periods (P < 0.01 in both the pooled
and random effects analyses). Of the sociodemo-
graphic characteristics examined, only marriage











Age -0.150† 0.013 0.013 0.053 0.025
Female -0.050 0.007 -0.001 0.098‡ 0.033
Non-Hispanic Caucasian -0.109‡ 0.004 0.022 -0.010 0.005
Married 0.0446 -0.016 -0.076 -0.157† -0.081§
Some college or more 0.029 0.019 -0.007 -0.050 0.010
Change in AD Dependence total score -0.427¶ -0.244¶ -0.197¶ -0.252¶ -0.235¶
Change in ADCS-ADL scale 0.533¶ 0.292¶ 0.269¶ 0.339¶ 0.299¶
Change in Neuropsychiatric Inventory -0.385¶ -0.157† -2.48¶ -0.190† -0.192¶
Change in Mini-Mental State Exam 0.295¶ 0.101‡ 0.103‡ 0.191† 0.136¶
Change in AD-Related Quality of Life 0.410¶ 0.276¶ 0.363¶ 0.362¶ 0.330¶
*Analyses report correlations between cross-sectional HUI-III scores and clinical/disease-speciﬁc indicators at baseline.
†P < 0.01, ‡P < 0.10, §P < 0.05, ¶P < 0.001.
n varies depending on the number of missing values.
ADCS-ADL,Alzheimer’s Disease Cooperative Study for Activities of Daily Living.
Table 4 Results of regression models of change in health utilities











Intercept 0.045 (0.158) 0.098 (0.166) 0.147 (0.173) 0.097 (0.095) 0.111 (0.128)
Age -0.001 (0.002) -0.001 (0.002) -0.002 (0.002) -0.002 (0.001) -0.002 (0.001)
Female 0.009 (0.028) -0.024 (0.031) 0.017 (0.032) 0.002 (0.017) -0.002 (0.023)
Non-Hispanic Caucasian 0.017 (0.032) 0.039 (0.034) 0.023 (0.035) 0.028 (0.019) 0.036 (0.027)
Married 0.018 (0.030) -0.062 (0.033)* -0.054 (0.034) -0.030 (0.018) -0.025 (0.026)
Some college or more -0.014 (0.028) -0.013 (0.030) -0.027 (0.031) -0.018 (0.017) -0.015 (0.022)
Change—AD Dependence level -0.008 (0.007) -0.006 (0.008) -0.009 (0.007) -0.009 (0.004)† -0.009 (0.004)†
Change—ADCS-ADL total score 0.006 (0.001) 0.003 (0.001)† 0.005 (0.001)‡ 0.004 (0.001)‡ 0.004 (0.001)‡
Change—Neuropsychiatric Inventory -0.001 (0.001) -0.001 (0.001)* -0.000 (0.001) -0.001 (0.000)† -0.001 (0.000)†
Change—Mini-Mental State Exam 0.002 (0.004) -0.002 (0.004) 0.001 (0.004) 0.000 (0.002) 0.000 (0.002)
Change—AD-Related Quality of Life 0.003 (0.001)§ 0.004 (0.001)‡ 0.004 (0.001)‡ 0.004 (0.001)‡ 0.004 (0.001)‡
Adjusted R2 0.1419 0.1477 0.2042 0.1773 -364.7¶
N 324 277 270 871 871
*P < 0.10, †P < 0.05, ‡P < 0.001, §P < 0.01.
¶2 Log likelihood.
ADCS-ADL,Alzheimer’s Disease Cooperative Study for Activities of Daily Living.
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showed a marginally signiﬁcant association with
change in HUI-III scores (P < 0.10), with married
patients having changes in HUI score -0.062 points
lower at 6 months than with nonmarried patients.
Discussion
Although several studies have examined the associa-
tion between clinical/disease-speciﬁc indicators and
health utility scores in AD patients [24,34–37], none
have used longitudinal data to examine the relation-
ship between change in health utilities and a broad
range of measures of cognitive performance, psychiat-
ric symptoms, functional capacity, quality of life, and
sociodemographic factors. We presented utility esti-
mates at four points in time using data deriving from
the CATIE-AD trial. On average, proxy-rated utilities
estimated with the HUI-III declined progressively from
baseline (0.18) to 9 months postrandom assignment
(0.12). This decrease occurred concurrently with an
average 9-month decline in MMSE scores of 2.3
points, which corresponds to a decrease of approxi-
mately 3.0 points over 12 months, very close to the
average decline of 3.3 points (95% conﬁdence interval
2.9–3.7) reported in 37 previous studies of AD patients
[48]. There was also a concurrent decrease in func-
tional status, in addition to concurrent increases in
behavioral symptoms, AD-related dependence, and
quality of life as measured using the ADRQoL.
Though the latter ﬁnding is somewhat surprising, as
one might suspect that quality of life would decline
with progression of the disease, it is also reﬂected, in
part, in the only other study to report changes in
ADRQoL scores over time. Although Lyketsos et al.
[59] reported a small signiﬁcant decline in average
ADRQoL score among a cohort of 47 persons with
dementia residing in a long-term care facility, for
nearly half (49%) ADRQoL scores did not change or
improved over the 2-year study period. Perhaps
aspects of the CATIE study design, including the pro-
vision of information, education, and counseling, led
caregivers to rate AD-Related Quality of Life more
positively than before participating.
One nationally representative study found mean
HUI-III scores for the general US adult and 65 and older
populations of 0.81 and 0.70, respectively [60]. Not
surprisingly, these estimates are substantially higher
than those found among AD patients in the present
study (0.12 to 0.18). Perhaps the major reason that AD
patients have considerably lower HUI-III is the high
prevalence of functional impairment found over and
above that associated with other conditions. This is
reﬂected in extant research which reveals associations
between cognitive impairment, major depression, and
other psychiatric disorders and medical morbidity,
pain, mortality, functional decline, and difﬁculties in
performing basic and instrumental activities [61,62].
AD patients in our study also had slightly lower
HUI-III scores than those reported for AD patients
elsewhere. Whereas Naglie et al. [35] report mean
proxy-ratedHUI-III scores of 0.23 among a small group
of 20 AD patients, Neumann et al. [36] report mean
proxy-ratedHUI-III scores of 0.22 among 679 patients.
One possible reason for the modest discrepancy
between ourHUI-III ratings and others is that our study
relied exclusively on patients with more serious psychi-
atric symptoms, including those with clinically severe
delusions, hallucinations, aggression, or agitation,
occurring after the onset of symptoms of dementia.
Thus, whereas mean MMSE scores among our sample
ranged from 15.0 to 12.7 (from baseline to 9 months),
mean MMSE score among patients in Naglie et al. [35]
was 18.9, with more than half being in the 19 to 26
range. Perhaps even more instructively, mean HUI-III
scores in our sample more closely approximated scores
found among patients who received a diagnosis of
moderate to severe AD in Neumann et al. [36] (0.19–
0.06, respectively) than those who received a diagnosis
as questionable and mild (0.47 and 0.39).
Mean HUI-III scores observed in the present study
(0.12 to 0.18) were also considerably lower than mean
health utility scores reported for AD patients using
other instruments. Thus, Jonsson et al. [37] reported
average caregiver-rated utilities using the EQ-5D of
0.52 and 0.51, respectively, for AD patients with
MMSE scores in the 15 to 20 and 10 to 15 ranges,
Neumann et al. [36]mean caregiver-ratedHUI-II scores
of 0.53 and 0.38 among AD patients with moderate
and severe Alzheimer’s, and Kerner et al. [34] mean
caregiver-rated QWB scores of 0.51 among patients
with probable or possible AD. That utility estimates in
AD patients tend to be substantially lower when mea-
sured using the HUI-III than when using HUI-II, QWB
and EQ-5D has also been found in studies directly
comparing HUI-III estimates to those of other instru-
ments in the same study [35,36]. One major reason for
the discrepancy between the HUI-III and QWB and
EQ-5D is that the HUI-III incorporates signiﬁcantly
more information on cognition than the QWB, whereas
the EQ-5D incorporates none. There are also signiﬁcant
differences between the HUI-III and HUI-II in this area,
with the HUI-III, for example, including additional
levels with which to describe cognitive impairment (6
vs. 4) and cognition being given greater weight in the
formula used to calculate global utility. Though varia-
tion in utility estimates raises questions as to which
instrument should be used in cost-effectiveness analyses
of AD-related treatments and therapies, it would seem
that greater emphasis on cognitive impairment makes
the HUI-III better equipped to measure utilities in
patients with AD or other dementia.
In general, signiﬁcant correlations between changes
in the HUI-III and ﬁve clinical/disease-speciﬁc indica-
tors fell in the directions expected, thereby supporting
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the construct validity of the HUI-III in AD patients.
Thus, although results reveal largely nonsigniﬁcant
multivariate relationships between change in HUI-III
scores and psychiatric symptoms (the NPI), cognitive
performance (the MMSE), and social and occupational
functioning (AD Dependence Scale total score), they
nonetheless reveal weak to moderate bivariate relation-
ships between changes in these scales and the HUI-III,
and in so doing, support the notion that more depen-
dent AD patients with greater behavioral symptoms
and cognitive impairment tend to have lower health
utility scores.
Moreover, even stronger evidence regarding the
validity of the HUI-III derives from highly signiﬁcant
associations between change in HUI-III scores and
physical functioning (the ADCS-ADL scale) and
quality of life (the ADRQoL scale), even after control-
ling for other factors, with more physically impaired
AD patients with poorer qualities of life tending to
have lower health utility scores. Overall, these ﬁndings
are consistent with those of previous studies demon-
strating the validity of health utility analysis in AD.
This is reﬂected in Neumann et al. [24,36] which
found an inverse relationship between global utility
scores deriving from the HUI-II and HUI-III and AD
stage, as well as Kerner et al. [34], which found
expected associations between QWB scores in AD and
measures of cognitive functioning, behavioral impair-
ment, and psychiatric distress. It is also reﬂected in
Naglie et al. [35], which reported moderate to weak
correlations between health utility scores deriving
from the EQ-5D, QWB and HUI-III, and measures of
general health status, functional impairment, comor-
bidity, mood and cognition, and in Jonsson et al. [37],
which reported a decline in global utility scores
deriving from the EQ-5D across ﬁve MMSE-deﬁned
severity levels, in addition to signiﬁcant associations
between proxy-rated utilities at different points in time
and cognitive performance and behavior.
Though ﬁndings provide evidence supporting the
construct validity of the HUI-III as a measure of health
utilities in AD patients, only 14% to 20% of the vari-
ance in HUI-III scores could be explained across the
four linear regression models estimated. As such, these
results are akin to those reported by Jonsson et al.
[37], which found that only 12% to 28% of the vari-
ance in EQ-5D-based utilities could be explained as a
function of the sociodemographic and clinical charac-
teristics examined (i.e., the MMSE and brief NPI). In
contrast, our ﬁndings vary somewhat from those re-
ported by Neumann et al. [36], who found that 51%
and 44% of the variance in HUI-II- and HUI-III-based
utilities could be explained as a function of patient
sociodemographics and AD stage determined using the
Clinical Dementia Rating (CDR) scale.
In cost-utility analysis, variance explained is a
concern because it determines the extent to which
results from analyses such as these may be used to
produce equations for translating more commonly
collected disease/clinical and health-status data into
health utility scores. While generic preference-based
instruments have been used to generate QALYs for use
in the pharmacoeconomic evaluation of AD treatments
[40,41], they are more often excluded from clinical
trials and other studies because of the additional costs
and burdens of data collection [18]. Though diagnosis-
speciﬁc scales provide opportunities to measure
disease-speciﬁc issues in-depth, they are not as easily
used, nor as preferred, for pharmacoeconomic evalu-
ation as preference-based utilities. Consequently, it
would be particularly useful if results from analyses
such as ours could be used to develop mapping func-
tions for generating QALYs for inclusion in pharma-
coeconomic evaluation from data deriving from
previously completed studies that eschewed direct
measurement of health utility.
The potential usefulness of such an endeavor is
reﬂected, in part, in numerous studies that have exam-
ined the relationship between preference-based indices
and more frequently collected health proﬁle measures
such as the SF-12 and SF-36. In general, these studies
conclude that performance on the latter explains 50 to
61% of the variance in the former, thereby supporting
development of equations translating SF-12 and SF-36
into HUI-, EuroQoL-, and QWB-based health utility
scores [63–66]. Clearly, our AD/clinical-speciﬁc ﬁnd-
ings fall well short of the 50% threshold established by
efforts to translate the SF-12 and SF-36 into health
utilities. Though far from ideal, results from Neumann
et al. [36] fall somewhat closer, perhaps because the
HUI-III does a decent job of distinguishing among
relative broad CDR-based severity levels (i.e., question-
able, mild, moderate, severe, profound, terminal) while
lacking sufﬁcient sensitivity to distinguish among more
subtle clinical/disease-speciﬁc differences. Because there
is evidence that theMMSE performs well as a surrogate
measure for the CDR for the staging of dementia [67],
future research should examine whether conversion of
MMSE scores to CDR states improves model ﬁt beyond
what we identiﬁed here.
The present study breaks new ground by using a
longitudinal data set to examine the sociodemographic
and clinical correlates of health utility scores in
patients with AD. Indeed, CATIE-AD was an intensive
study that included a comprehensive combination of
indicators measuring health utilities, cognitive perfor-
mance, behavioral disturbances, functional capacity,
and AD-Related Quality of Life. To our knowledge, no
previous longitudinal study collected such a broad
range of measures.
Despite the strength of this study, several limitations
require comment. First, results from our analyses may
be of limited generalizeability, both because of the
population studied and the nature of the CATIE inter-
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vention itself. On the one hand, the CATIE cohort
included relatively symptomatic AD cases thought to
potentially beneﬁt from antipsychotic pharmaco-
therapy. This is contrast to other studies, the vast
majority of which in one review (30 out of 37)
included cohorts with higher average MMSE scores at
baseline [48]. Furthermore, unlike the general popula-
tion of AD sufferers, all CATIE participants had active
caregivers and were treated for behavioral symptoms
using one of three SGAs or placebo. Moreover, all
participants and caregivers were given basic informa-
tion and education about AD, its course, clinical prob-
lems and management, while caregivers were offered
two counseling sessions during the ﬁrst 18 weeks and
could speak with staff members as needed. Though
our ﬁndings were remarkably consistent over time, a
longer follow-up period could also have unknown
effects on our results. Indeed, the limited duration of
the study period contributed to a lack of variance in
HUI-III scores; that is, from an average of 0.18 at
baseline to 0.12 at 9 months. On one hand, it is pos-
sible that average HUI-III scores would have continued
to decline over the course of a longer follow-up period,
perhaps strengthening the signiﬁcance of some of the
relationships observed. On the other hand, it is pos-
sible that utility scores of about 0.12 are at the ﬂoor of
practical ratings for the group of dementia outpatients
studied here. Though we were limited by the param-
eters of the CATIE trial itself, future research should
use longer observation periods where possible to better
assess the relevance of these two scenarios.
Another limitation concerns the way in which health
utilities were assessed in that we estimated them indi-
rectly using the HUI-III, a generic-preference-based
instrument, which is based on utility weights derived
from other populations. This approach differs from
direct utility assessment of patients using established
methods such as the standard gamble, time trade-off,
visual analog, or category-rating techniques, which
allow individuals to weigh the utility of different health
states themselves. Several studies have found differences
in utilities derived through direct and indirect assess-
ment, with directly assessed utilities typically being
higher than those assessed indirectly using the HUI-III
[29,68,69], even for patients with Alzheimer’s disease
[35]. Though we found weak to moderate bivariate
relationships between HUI-III scores and all clinical/
disease-speciﬁc measures, and signiﬁcant associations
between the HUI-III and ADCS-ADL and ADRQoL
after controlling for other factors, only a small propor-
tion of the variance in HUI-III scores could be
explained. It thus appears that the HUI-III may not be
sensitive to important AD-related impairments. Indeed,
previous research suggests that HUI-II- and HUI-III-
derived utilities for caregivers of patients with AD were
insensitive to setting of care and AD stage [6,24,36] and
that the HUI-III did not discriminate among older
people with no prior, a remote, or recent myocardial
infarction [26]. Because generic indices may lack sensi-
tivity to important differences in health status that are
salient to people with AD [25], direct measurement of
health utilities may be preferable, despite higher costs
and increased patient/caregiver burden. Alternatively,
energy could be directed toward developing preference-
based instruments speciﬁcally for measuring health
utilities among patients with AD, though this would
then preclude comparisons with other diseases and
non-AD-related interventions.
Finally, like most studies measuring health utilities
in people with AD or other dementia, we used data
deriving from proxy raters rather than patients them-
selves. Nevertheless, there remains the question as to
whether use of proxy- versus patient-derived utilities is
most appropriate, especially because proxy raters rou-
tinely rate impairments higher than patients do. This
is reﬂected in studies, which reveal lack of agreement
between utilities derived directly from people with
AD/dementia and caregiver proxies. Thus, Jonsson
et al. [37] found that mean EQ-5D-derived utility
scores among AD patients were signiﬁcantly higher
than mean proxy scores, with average patient utilities
varying little across MMSE-derived severity levels.
Councill et al. [70] found lack of inter-rater agreement
among proxy- and patient-completion of the EQ-5D
in persons with dementia; and Naglie et al. [35] found
that mean HUI-III-, EQ-5D-, and QWB-derived utili-
ties among AD patients were signiﬁcantly higher than
mean proxy scores, though disproportionately so for
the HUI-III, perhaps because of proxies typically
rating patients much lower on the HUI-III’s cognitive
item than patients themselves. There is little doubt
that cognitive impairment among patients with
AD/dementia limits their ability to make judgments
and reﬂect on their own experiences and to compre-
hend and respond to the HUI-III and other quality of
life questionnaires. Though the jury is still out on the
reliability of utility assessment in patients with mild
dementia, especially, say, when administered using a
facilitated interview [35,70], it is doubtful that self-
assessment would have been appropriate (or possible)
among the more advanced AD cases recruited for
CATIE. Clearly, further research is needed to deter-
mine the validity of proxy-rated utilities among
patients with AD, including those who may serve as
the most appropriate proxies for making such assess-
ments (i.e., primary caregivers or physicians).
Conclusion
With skyrocketing health-care costs and the continuing
development of new therapies and interventions, cost-
effectiveness analysis is achieving growing saliency as a
means for guiding the allocation of increasingly scarce
health-care resources. Indeed, despite historical reluc-
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tance among US policymakers to use this technique
[71], the bipartisan legislation—“Enhanced Health
Care Value for All Act”—was recently introduced in
Congress to expand funding and support for compara-
tive effectiveness research of health services, including
medical devices, medical procedures, prescription
drugs, and other treatment [72]. Because experts
suggest that QALYs serve as the foundation for cost-
effectiveness analysis [19], precise measurement of
health utilities is critical for the future viability of this
approach as a policymaking tool, especially because
small differences in utilities can result in large differ-
ences in cost-effectiveness [38]. Though our ﬁndings
provide evidence supporting the construct validity of
the HUI-III as a measure of health utilities in AD
patients, only weak relationships were found between
change in the HUI and some clinical indicators. Fur-
thermore, although disease-speciﬁc measures of func-
tional capability and quality of life showed more
signiﬁcant associations, less than 20% of the variation
in health utility could be explained. Thus, despite the
presence of generally favorable associations, it is likely
that the presence of signiﬁcant cognitive impairment
and the need to rely on proxy raters may limit the
applicability of utility measurement in AD. Conse-
quently, the results of this analysis question the useful-
ness of utility measurement as an explicit end point in
clinical trials of AD patients, nor do they demonstrate
the usefulness of the utility metric when applied to
changes in speciﬁc states of health deﬁned, in part, by
a growth in the dependence of the patient on others.
These possible limitations in less advanced AD popu-
lations, i.e., those not requiring antipsychotic therapy,
are not clear, though it seems likely that individuals
with milder cases should be better able to express their
own values and preferences—even more so if expected
advances allow for even earlier and perhaps presymp-
tomatic diagnosis of the disease [73]. Additional
exploratory work is needed to support the use of utility
measures for health state measurement efforts associ-
ated with AD. In the meantime, cost-effectiveness
analyses of AD interventions should incorporate
complimentary measures of net beneﬁts, including,
perhaps, improvements in psychiatric symptoms,
cognitive performance, functional capacity, and
AD-Related Quality of Life.
Source of ﬁnancial support: Wyeth Research, Philadelphia,
PA, USA.
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